VenoStent key facts
- Developer of a biomedical engineering technology designed to improve the quality and length of life for dialysis patients.
- It has raised $22.8M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Apr 2026.
- Notable investors include Y Combinator, Alumni Ventures, US National Science Foundation, MassChallenge, National Institutes of Health — 30 tracked in total.
- VenoStent has filed 2 Form Ds with the SEC since 2023, most recently May 2026 ($10.0M sold to 29 investors).
- Status: Privately Held (backing).
Who backs VenoStent
30+- ·The complete investor list: 30 names
- ·Watch VenoStent: the Monday email on marks, rounds and moves
VenoStent funding rounds
2 roundsHow much has VenoStent raised?
VenoStent has raised $22.8 million across 2 recorded rounds since 2023. The largest was a $16.1 million early-stage round in Jul 2023; the most recent was a $10 million early-stage round in Apr 2026.
VenoStent has filed 2 Form Ds with the SEC since 2023, most recently in May 2026 ($10 million sold to 29 investors).
VenoStent investors
30 investors are on record for VenoStent, including Y Combinator, Alumni Ventures, US National Science Foundation and MassChallenge. By type, the record holds 10 venture capital firms. The early-stage round in Apr 2026 drew 29 investors.
About VenoStent
Developer of a biomedical engineering technology designed to improve the quality and length of life for dialysis patients. The company's technology is made from a new class of shape-memory polymers used primarily as an external stent in coronary artery bypass surgery which requires no sutures, it uses the body's healing mechanisms to mimic the arterial environment in veins, and its net effect is improved AVF usability and durability, and quality and length of life, for chronic kidney disease (CKD) patients, enabling doctors to have a reduction in surgery time, risk of infection, and wound reopening of hemodialysis patients while also reducing failure from vein occlusion.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2015
- Employees
- 35
- Website
- venostent.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
VenoStent doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.